Researchers developed a saliva based SERS platform that detects epilepsy, Parkinson's disease, and schizophrenia by analyzing protein structural changes with up to 98% accuracy.

Explore the insights from Cenevo on the slow adoption of AI in drug discovery and the challenges faced by laboratories today.

Nightingale Health Plc | Stock Exchange Release | March 05, 2026 at 09:00:00 EET Nightingale Health Group's half-year report 1 July 2025 - 31 December 2025 (unaudited)Delivering clinical value for hea ...